| Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens Y Zheng, PA Valdez, DM Danilenko, Y Hu, SM Sa, Q Gong, AR Abbas, ... Nature medicine 14 (3), 282-289, 2008 | 2221 | 2008 |
| The IL‐17 pathway as a major therapeutic target in autoimmune diseases Y Hu, F Shen, NK Crellin, W Ouyang Annals of the New York Academy of Sciences 1217 (1), 60-76, 2011 | 184 | 2011 |
| IL-17RC is required for IL-17A–and IL-17F–dependent signaling and the pathogenesis of experimental autoimmune encephalomyelitis Y Hu, N Ota, I Peng, CJ Refino, DM Danilenko, P Caplazi, W Ouyang The Journal of Immunology 184 (8), 4307-4316, 2010 | 172 | 2010 |
| The IL-17 family cytokines in immunity and disease R Pappu, V Ramirez-Carrozzi, N Ota, W Ouyang, Y Hu Journal of clinical immunology 30, 185-195, 2010 | 168 | 2010 |
| A blood-based diagnostic test incorporating plasma Aβ42/40 ratio, ApoE proteotype, and age accurately identifies brain amyloid status: findings from a multi cohort validity … T West, KM Kirmess, MR Meyer, MS Holubasch, SS Knapik, Y Hu, ... Molecular neurodegeneration 16 (1), 30, 2021 | 152 | 2021 |
| Preclinical and clinical development of ABBV-8E12, a humanized anti-tau antibody, for treatment of Alzheimer’s disease and other tauopathies T West, Y Hu, PB Verghese, RJ Bateman, JB Braunstein, I Fogelman, ... J Prev Alzheimers Dis 4 (4), 236-241, 2017 | 151 | 2017 |
| Comparative proteomic analysis of intra-and interindividual variation in human cerebrospinal fluid Y Hu, JP Malone, AM Fagan, RR Townsend, DM Holtzman Molecular & Cellular Proteomics 4 (12), 2000-2009, 2005 | 149 | 2005 |
| Molecular Characterization of a Metastatic Neuroendocrine Cell Cancer Arising in the Prostates of Transgenic Mice* 210 Y Hu, JE Ippolito, EM Garabedian, PA Humphrey, JI Gordon Journal of Biological Chemistry 277 (46), 44462-44474, 2002 | 123 | 2002 |
| Anti-tau antibody administration increases plasma tau in transgenic mice and patients with tauopathy K Yanamandra, TK Patel, H Jiang, S Schindler, JD Ulrich, AL Boxer, ... Science translational medicine 9 (386), 2017 | 92 | 2017 |
| Helicobacter pylori attaches to NeuAcα2, 3Galβ1, 4 glycoconjugates produced in the stomach of transgenic mice lacking parietal cells AJ Syder, JL Guruge, Q Li, Y Hu, CM Oleksiewicz, RG Lorenz, SM Karam, ... Molecular cell 3 (3), 263-274, 1999 | 92 | 1999 |
| The PrecivityAD™ test: Accurate and reliable LC-MS/MS assays for quantifying plasma amyloid beta 40 and 42 and apolipoprotein E proteotype for the assessment of brain amyloidosis KM Kirmess, MR Meyer, MS Holubasch, SS Knapik, Y Hu, EN Jackson, ... Clinica Chimica Acta 519, 267-275, 2021 | 82 | 2021 |
| Identification and validation of novel CSF biomarkers for early stages of Alzheimer's disease Y Hu, A Hosseini, JSK Kauwe, J Gross, NJ Cairns, AM Goate, AM Fagan, ... PROTEOMICS–Clinical Applications 1 (11), 1373-1384, 2007 | 74 | 2007 |
| Assessment of a plasma amyloid probability score to estimate amyloid positron emission tomography findings among adults with cognitive impairment Y Hu, KM Kirmess, MR Meyer, GD Rabinovici, C Gatsonis, BA Siegel, ... JAMA network open 5 (4), e228392-e228392, 2022 | 58 | 2022 |
| RNA interference of achaete–scute homolog 1 in mouse prostate neuroendocrine cells reveals its gene targets and DNA binding sites Y Hu, T Wang, GD Stormo, JI Gordon Proceedings of the National Academy of Sciences 101 (15), 5559-5564, 2004 | 57 | 2004 |
| Blood-based biomarkers for Alzheimer’s disease: Current state and future use in a transformed global healthcare landscape H Hampel, Y Hu, J Cummings, S Mattke, T Iwatsubo, A Nakamura, ... Neuron 111 (18), 2781-2799, 2023 | 55 | 2023 |
| The foundation and architecture of precision medicine in neurology and psychiatry H Hampel, P Gao, J Cummings, N Toschi, PM Thompson, Y Hu, M Cho, ... Trends in Neurosciences 46 (3), 176-198, 2023 | 50 | 2023 |
| Novel therapeutic targets along the Th17 pathway W Ouyang, E Filvaroff, Y Hu, J Grogan European journal of immunology 39 (3), 670-675, 2009 | 41 | 2009 |
| Cross-reactive and bispecific anti-IL-17A/F antibodies Y Chen, YH Hu, W Ouyang, S Stawicki, Y Wu US Patent 8,790,642, 2014 | 21 | 2014 |
| [O2–17–01]: RESULTS OF A PHASE 1, SINGLE ASCENDING DOSE, PLACEBO‐CONTROLLED STUDY OF ABBV‐8E12 IN PATIENTS WITH PROGRESSIVE SUPRANUCLEAR PALSY AND PHASE 2 STUDY DESIGN IN EARLY … K Budur, T West, JB Braunstein, I Fogelman, YM Bordelon, I Litvan, ... Alzheimer's & Dementia 13 (7S_Part_12), P599-P600, 2017 | 10 | 2017 |
| Can we use blood biomarkers as entry criteria and for monitoring drug treatment effects in clinical trials? A report from the EU/US CTAD task force D Angioni, O Hansson, RJ Bateman, C Rabe, M Toloue, JB Braunstein, ... The Journal of Prevention of Alzheimer's Disease 10 (3), 418-425, 2023 | 9 | 2023 |
